Basel Medical Group (NASDAQ:BMGL – Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.31) earnings per share (EPS) for the quarter, reports. The firm had revenue of $3.14 million during the quarter.
Basel Medical Group Price Performance
BMGL stock opened at $5.04 on Friday. The firm has a 50-day moving average price of $4.37 and a 200-day moving average price of $6.51. Basel Medical Group has a 12 month low of $2.56 and a 12 month high of $18.72.
Analysts Set New Price Targets
Separately, Weiss Ratings lowered shares of Basel Medical Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 23rd. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.
Read Our Latest Report on BMGL
Basel Medical Group Company Profile
Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.
See Also
- Five stocks we like better than Basel Medical Group
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Basel Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basel Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
